Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.